Compare CABA & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | IBEX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.7M | 460.6M |
| IPO Year | 2019 | 2017 |
| Metric | CABA | IBEX |
|---|---|---|
| Price | $2.63 | $35.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | $14.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 6.7M | 108.1K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.26 | ★ 28.26 |
| EPS | N/A | ★ 2.54 |
| Revenue | N/A | ★ $558,273,000.00 |
| Revenue This Year | N/A | $14.13 |
| Revenue Next Year | N/A | $5.68 |
| P/E Ratio | ★ N/A | $13.70 |
| Revenue Growth | N/A | ★ 9.77 |
| 52 Week Low | $1.26 | $25.94 |
| 52 Week High | $4.23 | $42.99 |
| Indicator | CABA | IBEX |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 73.02 |
| Support Level | $2.11 | $33.79 |
| Resistance Level | $3.40 | $39.65 |
| Average True Range (ATR) | 0.23 | 0.99 |
| MACD | -0.03 | 0.38 |
| Stochastic Oscillator | 4.72 | 99.52 |
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.